Carol Aghajanian
Overview
Explore the profile of Carol Aghajanian including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
242
Citations
10064
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zammarrelli 3rd W, Nandakumar S, Kertowidjojo E, Nguyen B, Moukarzel L, Da Cruz Paula A, et al.
Gynecol Oncol
. 2025 Mar;
195:89-97.
PMID: 40081112
Objective: The molecular underpinnings of primary treatment-naïve endometrial carcinoma (EC) are well described. Here we sought to characterize the genomic landscape of distant metastatic EC. Methods: Distant metastatic ECs from...
2.
Bae-Jump V, Sill M, Gehrig P, Merker J, Corcoran D, Pfefferle A, et al.
Gynecol Oncol
. 2025 Mar;
195:66-74.
PMID: 40056832
Introduction: We evaluated the efficacy of the addition of the anti-diabetic drug metformin to standard-of-care paclitaxel and carboplatin (PC) in patients with advanced and recurrent endometrial cancer (EC). Methods: In...
3.
Eskander R, Sill M, Beffa L, Moore R, Hope J, Musa F, et al.
Nat Med
. 2025 Mar;
PMID: 40044930
Historically, the treatment of patients with advanced stage or recurrent endometrial cancer included paclitaxel plus carboplatin. Immunotherapy in combination with chemotherapy resulted in improved clinical outcomes in several solid tumors....
4.
Praiss A, Park K, Makker S, Girshman J, Aghajanian C, Grisham R
Int J Gynecol Cancer
. 2025 Feb;
35(3):101638.
PMID: 39914268
Mesonephric and mesonephric-like adenocarcinomas of the gynecologic tract are a rare subset of gynecologic tumors that are frequently associated with the presence of somatic KRAS mutations. Owing to their rare...
5.
Finch L, Andres S, Iasonos A, Zhou Q, Girshman J, Chhetri-Long R, et al.
Int J Gynecol Cancer
. 2025 Jan;
35(1):100005.
PMID: 39878266
Objective: We sought to determine the safety and efficacy of the oral progesterone antagonist onapristone in combination with anastrozole in patients with recurrent progesterone receptor-positive adult-type granulosa cell tumor of...
6.
Liu Y, Mathews C, Simpkins F, Cadoo K, Provencher D, McCormick C, et al.
Cancer
. 2025 Jan;
131(2):e35707.
PMID: 39817648
Background: LIGHT (oLaparib In HRD-Grouped Tumor types; NCT02983799) prospectively evaluated olaparib treatment in patients with platinum-sensitive relapsed ovarian cancer (PSROC) assigned to cohorts by known BRCA mutation (BRCAm) and homologous...
7.
Mayadev J, Zamarin D, Deng W, Lankes H, Pesci G, Kim H, et al.
Nat Commun
. 2025 Jan;
16(1):553.
PMID: 39788967
Combined immune checkpoint blockade (ICB) and chemoradiation (CRT) is approved in patients with locally advanced cervical cancer (LACC) but optimal sequencing of CRT and ICB is unknown. NRG-GY017 (NCT03738228) was...
8.
Liu Y, Sia T, Varice N, Wu M, Byrne M, Khurram A, et al.
JCO Precis Oncol
. 2024 Dec;
8:e2400525.
PMID: 39715484
Purpose: Although germline genetic testing (GT) is recommended for all patients with ovarian cancer (OC) and some patients with endometrial cancer (EC), uptake remains low with multiple barriers. Our center...
9.
Barnicle A, Ray-Coquard I, Rouleau E, Cadoo K, Simpkins F, Aghajanian C, et al.
Genome Med
. 2024 Dec;
16(1):145.
PMID: 39695768
Background: The introduction of poly(ADP-ribose) polymerase (PARP) inhibitors represented a paradigm shift in the treatment of ovarian cancer. Genomic data from patients with high-grade ovarian cancer in six phase II/III...
10.
Liu Y, Praiss A, Chiang S, Devereaux K, Huang J, Rizzuto G, et al.
Gynecol Oncol
. 2024 Dec;
192:171-177.
PMID: 39674133
Objectives: To describe clinical outcomes and pearls for patients with gestational trophoblastic neoplasm (GTN). Methods: Patients with GTN treated at a referral center from 1/2006 to 12/2022 were included. Clinical...